| Literature DB >> 35013375 |
Mateusz Jagielski1, Jacek Piątkowski2, Marek Jackowski2.
Abstract
EUS-guided transmural endoscopic drainage is commonly used in the treatment of WOPN in the late phase of ANP. The role of endoscopic intervention remains unclear in the early phase of ANP. This study aimed to prospectively evaluate early endoscopic treatment of ANCs compared with endoscopic drainage of WOPN. Overall, 71 patients with ANP who underwent transmural endoscopic drainage for necrotic collections were included. Endoscopic intervention was performed within the first four weeks of ANP in 25 (35.21%) patients with ANC (Group 1) and in 46 (64.79%) patients after four weeks since the onset of ANP with WOPN (Group 2). The overall mean age of patients was 49.9 (22-79) years and 59 of them were males. The mean time of active drainage and duration of total endoscopic treatment was 26.8 and 16.9 days (P = 0.0001) and 270.8 and 164.2 days (P = 0.0001) in Groups 1 and 2, respectively. The average total number of endoscopic interventions was 9.5 and 4.5 in Groups 1 and 2, respectively (P = 0.0001). The clinical success rate, frequency of complications of endoscopic interventions, long-term success rate, and recurrence rate were not significantly different between the groups (P > 0.05 for each). Transmural endoscopic drainage is effective method of treatment of early ANCs within the first four weeks of ANP. However, compared with endoscopic intervention in WOPN, more interventions and longer duration of drainage are required.Entities:
Mesh:
Year: 2022 PMID: 35013375 PMCID: PMC8748752 DOI: 10.1038/s41598-021-03924-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Detailed characteristics of patients of the two groups.
| ANC ( | WOPN ( | Total ( | ||
|---|---|---|---|---|
| 0.1401 | ||||
| Female | 2 (8.0%) | 10 (21.7%) | 12 (16.9%) | |
| Male | 23 (92.0%) | 36 (78.3%) | 59 (83.1%) | |
| 0.0114 | ||||
| Mean (SD) | 44.0 (14.4) | 53.2 (13.9) | 49.9 (14.7) | |
| Range | 22.0–74.0 | 25.0–79.0 | 22.0–79.0 | |
| Median | 42.0 | 56.0 | 50.0 | |
| 95% CI | 38.1–50.0 | 49.0–57.3 | 46.5–53.4 | |
| 0.0699 | ||||
| Alcoholic | 20 (80.0%) | 27 (58.7%) | 47 (66.2%) | |
| Non-alcoholic | 5 (20.0%) | 19 (41.3%) | 24 (33.8%) | |
| 0.0001 | ||||
| Average (SD) | 16.4 (4.9) | 74.5 (45.9) | 54.0 (46.3) | |
| Range | 8.0–25.0 | 30.0–240.0 | 8.0–240.0 | |
| Median | 16.0 | 56.5 | 44.0 | |
| 95% CI | 14.3–18.4 | 60.9–88.1 | 43.1–65.0 | |
| 0.1662 | ||||
| Mean (SD) | 1.7 (1.1) | 1.3 (1.0) | 1.5 (1.1) | |
| Range | 0.0–4.0 | 0.0–4.0 | 0.0–4.0 | |
| Median | 2.0 | 1.0 | 1.0 | |
| 95% CI | 1.3–2.2] | 1.0–1.6 | 1.2–1.7 | |
| 0.0186 | ||||
| Mean (SD) | 3.3 (1.3) | 2.5 (1.2) | 2.8 (1.3) | |
| Range | 1.0–6.0 | 0.0–5.0 | 0.0–6.0 | |
| Median | 3.0 | 2.0 | 3.0 | |
| 95% CI | 2.8–3.9 | 2.2–2.9 | 2.5–3.1 | |
| 0.1324 | ||||
| Mean (SD) | 12.7 (4.1) | 11.0 (4.3) | 11.6 (4.3) | |
| Range | 6.0–20.0 | 2.0–21.0 | 2.0–21.0 | |
| Median | 13.0 | 10.5 | 11.0 | |
| 95% CI | 11.0–14.4 | 9.7–12.2 | 10.5–12.6 | |
| 0.0143 | ||||
| Mean (SD) | 3.8 (2.2) | 2.5 (1.1) | 3.0 (1.7) | |
| Range | 1.0–8.0 | 0.0–5.0 | 0.0–8.0 | |
| Median | 4.0 | 2.5 | 3.0 | |
| 95% CI | 2.9–4.7 | 2.1–2.8 | 2.6–3.4 | |
| 0.2062 | ||||
| Mean (SD) | 8.1 (1.3) | 7.7 (1.3) | 7.8 (1.3) | |
| Range | 6.0–10.0 | 5.0–10.0 | 5.0–10.0 | |
| Median | 8.0 | 7.0 | 8.0 | |
| 95% CI | 7.6–8.7 | 7.3–8.0 | 7.5–8.1 | |
| 0.0001 | ||||
| Mean (SD) | 185.2 (68.1) | 123.0 (47.7) | 144.9 (62.8) | |
| Range | 88.0–320.0 | 68.0–247.0 | 68.0–320.0 | |
| Median | 178.0 | 117.0 | 130.0 | |
| 95% CI | 157.1–213.3 | 108.9–137.2 | 130.1–159.8 | |
| 0.0027 | ||||
| 25%–50% | 0 (0.0%) | 9 (19.6%) | 9 (12.7%) | |
| 50%–75% | 7 (28.0%) | 22 (47.8%) | 29 (40.8%) | |
| > 75% | 18 (72.0%) | 15 (32.6%) | 33 (46.5%) | |
| 0.0132 | ||||
| Central | 0 (0.0%) | 9 (19.6%) | 9 (12.7%) | |
| Peripheral | 0 (0.0%) | 4 (8.7%) | 4 (5.6%) | |
| Mixed | 25 (100.0%) | 33 (71.7%) | 58 (81.7%) | |
SD, standard deviation; CI, confidence interval; ANC, acute necrotic collection; WOPN, walled-off pancreatic necrosis.
Indications for endoscopic treatment.
| ANC ( | WOPN ( | Total ( | ||
|---|---|---|---|---|
| Infection | 16 (64.0%) | 20 (43.5%) | 36 (50.7%) | 0.0985 |
| Subileus/ileus | 8 (32.0%) | 15 (32.6%) | 23 (32.4%) | 0.9583 |
| Icterus | 0 (0.0%) | 5 (10.9%) | 5 (7.0%) | 0.0873 |
| Abdominal pain | 0 (0.0%) | 15 (32.6%) | 15 (21.1%) | 0.0013 |
| Weight loss | 0 (0.0%) | 12 (26.1%) | 12 (16.9%) | 0.0051 |
| Abdominal compartment syndrome | 6 (24.0%) | 0 (0.0%) | 6 (8.5%) | 0.0005 |
Figure 1a–g Endoscopic treatment of acute necrotic collections. A 35-year-old male with acute necrotizing pancreatitis. On contrast-enhanced abdominal and pelvic computed tomography on day 8 of pancreatitis, extensive acute necrotic collections are visible (a, b). Because of symptoms of abdominal compartment syndrome, transmural endoscopic drainage of acute necrotic collections was performed. On fluoroscopy, the drainage system can be seen (c). During direct endoscopic debridement, solid necrotic masses within the lumen are visible (d, e). On control multiphase contrast-enhanced abdominal and pelvic computed tomography (f, g) after 6 months since the endoscopic treatment, complete regresion of necrotic collections was noted.
Figure 2a–g Endoscopic treatment of walled-off pancreatic necrosis. A 62-year-old female patient qualified for drainage of infected walled-off pancreatic necrosis on day 48 of acute necrotizing pancreatitis (a, b). Transmural endoscopic drainage (c) and numerous direct endoscopic necrosectomy procedures were performed (d, e). On control contrast-enhanced abdominal and pelvic computed tomography (f, g) after 12 months since the endoscopic treatment, a complete regression of necrotic collections was noted.
Parameters in laboratory blood test on day of the beginning of the endoscopic treatment.
| Parameter in blood test | ANC ( | WOPN ( | |
|---|---|---|---|
| Hemoglobin, | 12.6 (3.1) [8.3–18.4] | 13.8 (2.80) [8.6–17.7] | 0.144 |
| Leukocytes, | 18.5 (6.8) [7.7–32.08] | 13.09 (7.2) [6.1–31.01] | 0.008 |
| Thrombocytes, | 489.1 (133.8) [154.0–553.0] | 292.9 (125.9) [110.0–555.0] | 0.013 |
| C-reactive protein, | 225.7 (110.6) [58.8- 444.2] | 252.8 (105) [49.9–504.6] | 0.200 |
| Procalcitonin, | 3.65 (5.2) [0.09- 23.4] | 2.21 (3.5) [0.05–13.5] | 0.185 |
| Creatinine, | 2.0 (0.9) [0.8–2.6] | 1.8 (0.8) [0.8–2.8] | 0.052 |
| Amylase, U/L | 139.8 (119.4) [30–590] | 109.7 (76.8) [23–334] | 0.230 |
| Lipase, U/L | 117.9 (41.4) [51–222] | 82.5 (35.7) [23–166] | 0.015 |
| Bilirubin, | 2.3 (3.0) [0.4–13.6] | 1.9 (2.3) [0.5–10.0] | 0.204 |
| AST, | 226.7 (230.6) [45–1105] | 230 (184.4) [34–652] | 0.812 |
| ALT, | 218.9 (213.4) [51–1015] | 253.9 (205.2) [34–782] | 0.623 |
| D-dimer, mg/L | 1.28 (0.9) [0.39–4.6] | 0.96 (0.7) [0.5–3.55] | 0.731 |
Complications of endoscopic treatment.
| ANC ( | WOPN ( | Total ( | |
|---|---|---|---|
| Gastrointestinal bleeding (required transfusions) | 4 (16.0%) | 6 (13.04%) | 10 (14.08%) |
| Transmural stent migration into lumen of the collection (treated endoscopically) | 3 (12.0%) | 4 (8.7%) | 7 (9.86%) |
| Gastrointestinal perforation (treated conservatively) | 0 (0.0%) | 1 (2.17%) | 1 (1.4%) |